Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib-Reference-Cited by-同舟云学术

Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

Published:2012-05-30 Issue:136 Volume:4 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sen Banibrata¹,Peng Shaohua¹,Tang Ximing¹,Erickson Heidi S.¹,Galindo Hector¹²³,Mazumdar Tuhina¹,Stewart David J.¹,Wistuba Ignacio¹²,Johnson Faye M.¹⁴

Affiliation:

1. Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

2. Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

3. Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago 8331150, Chile.

4. The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.

Abstract

Induction of tumor cell senescence may explain the response of a patient with BRAF kinase–impaired lung cancer to the multikinase inhibitor dasatinib.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference34 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

3. The essence of senescence: Figure 1.

4. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

5. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02

2. Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review;Frontiers in Oncology;2024-03-27

3. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

4. Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors;Epigenetics;2024-02-18

5. Non-small-cell lung cancer: how to manage BRAF-mutated disease;Drugs in Context;2023-05-02